Metastatic Pancreatic Adecarcinoma clinical trials

Explore recruiting metastatic pancreatic adecarcinoma clinical trials.

Also recruiting in Europe

Metastatic Pancreatic Adecarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Pancreatic Adecarcinoma trials by city

Metastatic Pancreatic Adecarcinoma in Toronto Metastatic Pancreatic Adecarcinoma in Vancouver Metastatic Pancreatic Adecarcinoma in Montreal Metastatic Pancreatic Adecarcinoma in Calgary Metastatic Pancreatic Adecarcinoma in Edmonton Metastatic Pancreatic Adecarcinoma in Ottawa Metastatic Pancreatic Adecarcinoma in Winnipeg Metastatic Pancreatic Adecarcinoma in Quebec City Metastatic Pancreatic Adecarcinoma in Hamilton Metastatic Pancreatic Adecarcinoma in Kitchener Metastatic Pancreatic Adecarcinoma in London Metastatic Pancreatic Adecarcinoma in Halifax Metastatic Pancreatic Adecarcinoma in New York Metastatic Pancreatic Adecarcinoma in Los Angeles Metastatic Pancreatic Adecarcinoma in Chicago Metastatic Pancreatic Adecarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease